TY - JOUR
T1 - SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies
AU - Shrivastava, Shikha
AU - Carmen, Joshua M.
AU - Lu, Zhongyan
AU - Basu, Shraddha
AU - Sankhala, Rajeshwer S.
AU - Chen, Wei Hung
AU - Nguyen, Phuong
AU - Chang, William C.
AU - King, Jocelyn
AU - Corbitt, Courtney
AU - Mayer, Sandra
AU - Bolton, Jessica S.
AU - Anderson, Alexander
AU - Swafford, Isabella
AU - Terriquez, Guillermo D.
AU - Trinh, Hung V.
AU - Kim, Jiae
AU - Jobe, Ousman
AU - Paquin-Proulx, Dominic
AU - Matyas, Gary R.
AU - Gromowski, Gregory D.
AU - Currier, Jeffrey R.
AU - Bergmann-Leitner, Elke
AU - Modjarrad, Kayvon
AU - Michael, Nelson L.
AU - Joyce, M. Gordon
AU - Malloy, Allison M.W.
AU - Rao, Mangala
N1 - Publisher Copyright:
© 2023, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
PY - 2023/12
Y1 - 2023/12
N2 - This study demonstrates the impact of adjuvant on the development of T follicular helper (Tfh) and B cells, and their influence on antibody responses in mice vaccinated with SARS-CoV-2-spike-ferritin-nanoparticle (SpFN) adjuvanted with either Army Liposome Formulation containing QS-21 (SpFN + ALFQ) or Alhydrogel® (SpFN + AH). SpFN + ALFQ increased the size and frequency of germinal center (GC) B cells in the vaccine-draining lymph nodes and increased the frequency of antigen-specific naive B cells. A single vaccination with SpFN + ALFQ resulted in a higher frequency of IL-21-producing-spike-specific Tfh and GC B cells in the draining lymph nodes and spleen, S-2P protein-specific IgM and IgG antibodies, and elicitation of robust cross-neutralizing antibodies against SARS-CoV-2 variants as early as day 7, which was enhanced by a second vaccination. This was associated with the generation of high titer, high avidity binding antibodies. The third vaccination with SpFN + ALFQ elicited high levels of neutralizing antibodies against the Omicron variant. No cross-neutralizing antibodies against Omicron were induced with SpFN + AH. These findings highlight the importance of ALFQ in orchestrating early induction of antigen-specific Tfh and GC B cell responses and long-lived plasma cells in the bone marrow. The early engagement of S-2P specific naive B cells and high titer IgM antibodies shape the development of long-term neutralization breadth.
AB - This study demonstrates the impact of adjuvant on the development of T follicular helper (Tfh) and B cells, and their influence on antibody responses in mice vaccinated with SARS-CoV-2-spike-ferritin-nanoparticle (SpFN) adjuvanted with either Army Liposome Formulation containing QS-21 (SpFN + ALFQ) or Alhydrogel® (SpFN + AH). SpFN + ALFQ increased the size and frequency of germinal center (GC) B cells in the vaccine-draining lymph nodes and increased the frequency of antigen-specific naive B cells. A single vaccination with SpFN + ALFQ resulted in a higher frequency of IL-21-producing-spike-specific Tfh and GC B cells in the draining lymph nodes and spleen, S-2P protein-specific IgM and IgG antibodies, and elicitation of robust cross-neutralizing antibodies against SARS-CoV-2 variants as early as day 7, which was enhanced by a second vaccination. This was associated with the generation of high titer, high avidity binding antibodies. The third vaccination with SpFN + ALFQ elicited high levels of neutralizing antibodies against the Omicron variant. No cross-neutralizing antibodies against Omicron were induced with SpFN + AH. These findings highlight the importance of ALFQ in orchestrating early induction of antigen-specific Tfh and GC B cell responses and long-lived plasma cells in the bone marrow. The early engagement of S-2P specific naive B cells and high titer IgM antibodies shape the development of long-term neutralization breadth.
UR - http://www.scopus.com/inward/record.url?scp=85150880920&partnerID=8YFLogxK
U2 - 10.1038/s41541-023-00638-6
DO - 10.1038/s41541-023-00638-6
M3 - Article
AN - SCOPUS:85150880920
SN - 2059-0105
VL - 8
JO - npj Vaccines
JF - npj Vaccines
IS - 1
M1 - 43
ER -